Impact of CYP3A5 genotype on tacrolimus pharmacokinetics and clinical outcomes in pediatric patients with Henoch–Schönlein purpura nephritis

Pharmacogenetics and Genomics · Published 2026-05-19 · DOI 10.1097/fpc.0000000000000604

Free full text

Authors (10)

Huiying Li, Na Li, Xiaoling Tang, Fashuang Li, Danyang Ren, Jing Zong, Caixia Tu, Linbo Li, Lilin Zhang, Shaochun Yu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Li, H., Li, N., Tang, X., et al. (2026). Impact of CYP3A5 genotype on tacrolimus pharmacokinetics and clinical outcomes in pediatric patients with Henoch–Schönlein purpura nephritis. Pharmacogenetics and Genomics. https://doi.org/10.1097/fpc.0000000000000604

Related articles

• Updated analysis of the pharmacogenomics of pediatric bronchodilator response · Pharmacogenetics and Genomics · 2024 · Same journal
• Integrating pharmacogenetics in sport medicine: enhancing treatment precision and preventing unintentional doping violation · Pharmacogenetics and Genomics · 2025 · Same journal
• Pharmacogenomics of commonly used intravenous anesthetics · Pharmacogenetics and Genomics · 2025 · Same journal
• Application of risk priority number of failure mode and effects analysis to drug–variant pairs for severe cutaneous adverse reactions in Korean and American populations · Pharmacogenetics and Genomics · 2026 · Same journal
• Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity · Pharmacogenetics and Genomics · 2025 · Same journal
• Association of ADH1B and ALDH2 genotypes with the risk of lung adenocarcinoma · Pharmacogenetics and Genomics · 2024 · Same journal
• Association of estrogen and progesterone receptor polymorphisms with idiopathic thin endometrium · Pharmacogenetics and Genomics · 2025 · Same journal
• No interaction between genetic variants and DNA methylation of the ferrochelatase gene in relation to antituberculosis drug-induced liver injury · Pharmacogenetics and Genomics · 2025 · Same journal
• Individualized perampanel response and efficacy in patients with refractory epilepsy: the need for ATP-binding cassette B1 genotyping and therapeutic drug monitoring to work in tandem · Pharmacogenetics and Genomics · 2026 · Same journal
• Metabolic effects of heterocyclic amines on insulin‑induced AKT phosphorylation and gluconeogenic gene expression are modified by N-acetyltransferase 2 genetic polymorphism · Pharmacogenetics and Genomics · 2025 · Same journal